Donald Ronning

Dr. Donald Ronning

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2015 in Analytical Chemistry
Verified
Journal Article
Closed access
KCKevin D. Clark
Kevin D. Clark
ONOmprakash Nacham
Omprakash Nacham
HYHonglian Yu
Honglian Yu
TLTianhao Li
Tianhao Li
MYMelissa M. Yamsek
Melissa M. Yamsek
JAJared L. Anderson
Jared L. Anderson

26 February 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
VSVivek Sharma
Vivek Sharma
AAArulandu Arockiasamy
Arulandu Arockiasamy
DRDonald Ronning
Donald Ronning
CSChristos G. Savva
Christos G. Savva
AHAndreas Holzenburg
Andreas Holzenburg
JSJames C Sacchettini
James C Sacchettini
In bacteria, the majority of exported proteins are translocated by the Sec system, which recognizes the signal sequence of a preprotein and uses ATP and the proton motive force to mediate protein translocation across the cytoplasmic membrane. SecA is an essential protein component of this system, containing the molecular motor that facilitates translocation. Here we report the three-dimensional structure of the SecA protein of Mycobacterium tuberculosis . Each subunit of the homodimer contains a “motor” domain and a translocation domain. The structure predicts that SecA can interact with the SecYEG pore and function as a molecular ratchet that uses ATP hydrolysis for physical movement of the preprotein. Knowledge of this structure provides a framework for further elucidation of the translocation process.

1 February 2000 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
JSJames C. Sacchettini
James C. Sacchettini
DRDonald Ronning
Donald Ronning
TKThomas Klabunde
Thomas Klabunde
GBGurdyal S. Besra
Gurdyal S. Besra
VVVaralakshmi D. Vissa
Varalakshmi D. Vissa
JBJohn T. Belisle
John T. Belisle

1 January 2008 in Cell
Verified
Journal Article
Closed access
OBOrsolya Barabas
Orsolya Barabas
DRDonald Ronning
Donald Ronning
CGCatherine Guynet
Catherine Guynet
AHAlison Burgess Hickman
Alison Burgess Hickman
BTBao Ton-Hoang
Bao Ton-Hoang
FDFred Dyda
Fred Dyda

6 November 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
LFLorenza Favrot
Lorenza Favrot
AGAnna E. Grzegorzewicz
Anna E. Grzegorzewicz
DLDaniel H. Lajiness
Daniel H. Lajiness
RMRachel K. Marvin
Rachel K. Marvin
JBJulie Boucau
Julie Boucau
DRDonald Ronning
Donald Ronning
The increasing prevalence of drug-resistant tuberculosis highlights the need for identifying new antitubercular drugs that can treat these infections. The antigen 85 (Ag85) complex has emerged as an intriguing mycobacterial drug target due to its central role in synthesizing major components of the inner and outer leaflets of the mycobacterial outer membrane. Here we identify ebselen (EBS) as a potent inhibitor of the Mycobacterium tuberculosis Ag85 complex. Mass spectrometry data show that EBS binds covalently to a cysteine residue (C209) located near the Ag85C active site. The crystal structure of Ag85C in the presence of EBS shows that C209 modification restructures the active site, thereby disrupting the hydrogen-bonded network within the active site that is essential for enzymatic activity. C209 mutations display marked decreases in enzymatic activity. These data suggest that compounds using this mechanism of action will strongly inhibit the Ag85 complex and minimize the selection of drug resistance.

1 August 2002 in Molecular Cell
Verified
Journal Article
Closed access
AHAlison Burgess Hickman
Alison Burgess Hickman
DRDonald Ronning
Donald Ronning
RKRobert M Kotin
Robert M Kotin
FDFred Dyda
Fred Dyda